Evidence map›Paper›PMID 27766572›Full record

ArticlePathology oncology research : POR2017

Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients.

Masaru Ide, Shinichi Koba, Naoko Sueoka-Aragane, Akemi Sato, Yuri Nagano, Takuya Inoue, Noriyuki Misago, Yutaka Narisawa, Shinya Kimura, Eisaburo Sueoka

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Masaru IdeDepartment of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Shinichi KobaDepartment of Dermatology, Faculty of Medicine, Saga University, Saga, Japan.
Naoko Sueoka-AraganeDepartment of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Akemi SatoDepartment of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Yuri NaganoDepartment of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Takuya InoueDepartment of Dermatology, Faculty of Medicine, Saga University, Saga, Japan.
Noriyuki MisagoDepartment of Dermatology, Faculty of Medicine, Saga University, Saga, Japan.
Yutaka NarisawaDepartment of Dermatology, Faculty of Medicine, Saga University, Saga, Japan.
Shinya KimuraDepartment of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Eisaburo SueokaDepartment of Clinical Laboratory Medicine, Faculty of Medicine, Saga University, Saga, 849-8501, Japan. sueokae@cc.saga-u.ac.jp.
Saga University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRAF gene mutations have been observed in 30-50 % of malignant melanoma patients. Recent development of therapeutic intervention using BRAF inhibitors requires an accurate and rapid detection system for BRAF mutations. In addition, the clinical characteristics of the melanoma associated with BRAF mutations in Japanese patients have not been investigated on a large scale evaluation. We recently established quenching probe system (QP) for detection of an activating BRAF mutation, V600E and evaluated 113 melanoma samples diagnosed in Saga University Hospital from 1982 to 2011. The QP system includes fully automated genotyping, based on analysis of the probe DNA melting curve, which binds the target mutated site using a fluorescent guanine quenched probe. BRAF mutations were detected in 54 of 115 (47 %) including 51 of V600E and 3 of V600 K in Japanese melanoma cases. Among clinical subtypes of melanoma, nodular melanoma showed high frequency (12 of 15; 80 %) of mutation followed by superficial spreading melanoma (13 of 26; 50 %). The QP system is a simple and sensitive method to determine BRAF V600E mutation, and will be useful tool for patient-oriented therapy with BRAF inhibitors.

introduction

Indexed as

AgedAsian PeopleCell Line, TumorDNA Mutational AnalysisFemaleGenotypeHumansMaleMelanomaMiddle AgedMutationProto-Oncogene Proteins B-rafSkin NeoplasmsBRAF protein, humanProto-Oncogene Proteins B-rafB-rafMelanomaMolecular targeted therapyTyrosine kinase inhibitors

Identifiers

PMID27766572
OpenAlexW2537317886

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.